Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12533452 | 1.00 | PSIP1 (0.32) | PSIP1CSNK2A2KDRCSNK2BCSNK2A1 | |
| SCHEMBL12533599 | 0.88 | PSIP1 (0.33) | PSIP1CSNK2A2KDRCSNK2BCSNK2A1 | |
| SCHEMBL14405278 | 0.88 | PSIP1 (0.33) | PSIP1CSNK2A2KDRCSNK2BCSNK2A1 | |
| SCHEMBL12533451 | 0.88 | PSIP1 (0.41) | PSIP1 | |
| SCHEMBL13862927 | 0.84 | — | — | |
| SCHEMBL12533463 | 0.82 | USP2 (0.31) | — | |
| SCHEMBL12533465 | 0.82 | PSIP1 (0.34) | PSIP1 | |
| SCHEMBL12992709 | 0.77 | PSIP1 (0.45) | PSIP1 | |
| SCHEMBL10157239 | 0.77 | MEN1 (0.45) | PSIP1 | |
| SCHEMBL14405279 | 0.76 | PSIP1 (0.43) | PSIP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2574610-A1 | Inhibitors of human immonodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2013-04-03 | — | — | EP | disclosed |
| US-7956068-B2 | Inhibitors of human immunodeficiency virus replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-07 | — | — | US | disclosed |
| US-7956068-B2 | Inhibitors of human immunodeficiency virus replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-07 | — | — | US | disclosed |
| US-20100305115-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305115-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| WO-2009062288-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305115-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | CCNY, RTF2, POLR2E | PSIP1 1240/4885CSNK2A2 1024/4885KDR 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.